Clear Street raised the firm’s price target on Delcath Systems (DCTH) to $28 from $27 and keeps a Buy rating on the shares. The stock is trading lower on the company’s “soft” preliminary Q3 results and 2025 revenue guidance, the analyst tells investors in a research note. However, the firm attributes the results to pricing dynamics and new patient starts, which it feels are “likely a blip.” The CHOPIN trial results will lead to increased penetration of Hpezato into the metastatic uveal melanoma population, contends Clear Street. The firm sees today’s selloff as a buying opportunity. The stock is down 5% to $11.38 in midday trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCTH:
- Delcath Systems price target lowered to $30 from $31 at H.C. Wainwright
- Delcath Systems: Promising Growth Potential Amidst Challenges with Strong Buy Rating
- Delcath Systems Reports Positive CHOPIN Trial Results
- Delcath Systems announces investigator-initiated CHOPIN Phase 2 presentation
- Delcath Systems management to meet with Craig-Hallum